EdgarLookup

Amcor plc — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Amcor plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-0.8%
Profit Margin
Net income ÷ revenue
-0.1%
Return on Assets
Net income ÷ assets
2.16x
Debt-to-Equity
Total liabilities ÷ equity
+52.5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $5.08B Aug 15, 2025
FY2025 Mar 31, 2025 $3.33B Aug 15, 2025
FY2025 Dec 31, 2024 $3.24B Aug 15, 2025
FY2025 Sep 30, 2024 $3.35B Aug 15, 2025
FY2025 Jun 30, 2024 $3.54B Aug 15, 2025
FY2025 Mar 31, 2024 $3.41B Aug 15, 2025
FY2025 Dec 31, 2023 $3.25B Aug 15, 2025
FY2025 Sep 30, 2023 $3.44B Aug 15, 2025
FY2020 Jun 30, 2020 $3.14B Aug 27, 2020
FY2020 Mar 31, 2020 $3.14B Aug 27, 2020

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $15.01B Aug 15, 2025
FY2025 Jun 30, 2024 $13.64B Aug 15, 2025
FY2025 Jun 30, 2023 $14.69B Aug 15, 2025
FY2024 Jun 30, 2022 $14.54B Aug 16, 2024
FY2023 Jun 30, 2021 $12.86B Aug 17, 2023
FY2022 Jun 30, 2020 $12.47B Aug 18, 2022
FY2021 Jun 30, 2019 $9.46B Aug 24, 2021
FY2020 Jun 30, 2018 $9.32B Aug 27, 2020

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $895.00M Aug 15, 2025
FY2025 Mar 31, 2025 $654.00M Aug 15, 2025
FY2025 Dec 31, 2024 $626.00M Aug 15, 2025
FY2025 Sep 30, 2024 $659.00M Aug 15, 2025
FY2025 Jun 30, 2024 $754.00M Aug 15, 2025
FY2025 Mar 31, 2024 $692.00M Aug 15, 2025
FY2025 Dec 31, 2023 $621.00M Aug 15, 2025
FY2025 Sep 30, 2023 $645.00M Aug 15, 2025
FY2025 Jun 30, 2023 $2.73B Aug 15, 2025
FY2024 Jun 30, 2022 $2.82B Aug 16, 2024

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($39.00M) Aug 15, 2025
FY2025 Mar 31, 2025 $196.00M Aug 15, 2025
FY2025 Dec 31, 2024 $163.00M Aug 15, 2025
FY2025 Sep 30, 2024 $191.00M Aug 15, 2025
FY2025 Jun 30, 2024 $257.00M Aug 15, 2025
FY2025 Mar 31, 2024 $187.00M Aug 15, 2025
FY2025 Dec 31, 2023 $134.00M Aug 15, 2025
FY2025 Sep 30, 2023 $152.00M Aug 15, 2025
FY2025 Jun 30, 2023 $1.05B Aug 15, 2025
FY2024 Jun 30, 2022 $805.00M Aug 16, 2024

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.01B Aug 15, 2025
FY2025 Jun 30, 2024 $1.21B Aug 15, 2025
FY2025 Jun 30, 2023 $1.51B Aug 15, 2025
FY2024 Jun 30, 2022 $1.24B Aug 16, 2024
FY2023 Jun 30, 2021 $1.32B Aug 17, 2023
FY2022 Jun 30, 2020 $994.00M Aug 18, 2022
FY2021 Jun 30, 2019 $792.00M Aug 24, 2021
FY2020 Jun 30, 2018 $993.90M Aug 27, 2020
FY2019 Jun 30, 2017 $916.10M Sep 3, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $120.00M Aug 15, 2025
FY2025 Jun 30, 2024 $106.00M Aug 15, 2025
FY2025 Jun 30, 2023 $101.00M Aug 15, 2025
FY2024 Jun 30, 2022 $96.00M Aug 16, 2024
FY2023 Jun 30, 2021 $100.00M Aug 17, 2023
FY2022 Jun 30, 2020 $97.00M Aug 18, 2022
FY2021 Jun 30, 2019 $64.00M Aug 24, 2021
FY2020 Jun 30, 2018 $72.70M Aug 27, 2020
FY2019 Jun 30, 2017 $69.10M Sep 3, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.21B Aug 15, 2025
FY2025 Jun 30, 2024 $1.09B Aug 15, 2025
FY2025 Jun 30, 2023 $1.09B Aug 15, 2025
FY2024 Jun 30, 2022 $1.28B Aug 16, 2024
FY2023 Jun 30, 2021 $1.29B Aug 17, 2023
FY2022 Jun 30, 2020 $1.39B Aug 18, 2022
FY2021 Jun 30, 2019 $999.00M Aug 24, 2021
FY2020 Jun 30, 2018 $793.20M Aug 27, 2020
FY2019 Jun 30, 2017 $850.20M Sep 3, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.39B Aug 15, 2025
FY2025 Jun 30, 2024 $1.32B Aug 15, 2025
FY2025 Jun 30, 2023 $1.26B Aug 15, 2025
FY2024 Jun 30, 2022 $1.53B Aug 16, 2024
FY2023 Jun 30, 2021 $1.46B Aug 17, 2023
FY2022 Jun 30, 2020 $1.38B Aug 18, 2022
FY2021 Jun 30, 2019 $776.00M Aug 24, 2021
FY2020 Jun 30, 2018 $871.40M Aug 27, 2020
FY2019 Jun 30, 2017 $908.90M Sep 3, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2019 Jun 30, 2019 $332.20M Sep 3, 2019
FY2019 Jun 30, 2018 $365.00M Sep 3, 2019
FY2019 Jun 30, 2017 $379.30M Sep 3, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $37.07B Aug 15, 2025
FY2025 Jun 30, 2024 $16.52B Aug 15, 2025
FY2024 Jun 30, 2023 $17.00B Aug 16, 2024
FY2023 Jun 30, 2022 $17.43B Aug 17, 2023
FY2022 Jun 30, 2021 $17.19B Aug 18, 2022
FY2021 Jun 30, 2020 $16.44B Aug 24, 2021
FY2020 Jun 30, 2019 $17.17B Aug 27, 2020
FY2019 Jun 30, 2018 $9.06B Sep 3, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $25.33B Aug 15, 2025
FY2025 Jun 30, 2024 $12.57B Aug 15, 2025
FY2024 Jun 30, 2023 $12.91B Aug 16, 2024
FY2023 Jun 30, 2022 $13.29B Aug 17, 2023
FY2022 Jun 30, 2021 $12.37B Aug 18, 2022
FY2021 Jun 30, 2020 $11.76B Aug 24, 2021
FY2020 Jun 30, 2019 $11.49B Aug 27, 2020
FY2019 Jun 30, 2018 $8.36B Sep 3, 2019

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $11.73B Aug 15, 2025
FY2025 Jun 30, 2024 $3.88B Aug 15, 2025
FY2024 Jun 30, 2023 $4.03B Aug 16, 2024
FY2023 Jun 30, 2022 $4.08B Aug 17, 2023
FY2022 Jun 30, 2021 $4.76B Aug 18, 2022
FY2021 Jun 30, 2020 $4.63B Aug 24, 2021
FY2020 Jun 30, 2019 $5.61B Aug 27, 2020
FY2019 Jun 30, 2018 $626.60M Sep 3, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $11.28B Aug 15, 2025
FY2025 Jun 30, 2024 $5.35B Aug 15, 2025
FY2025 Jun 30, 2023 $5.37B Aug 15, 2025
FY2024 Jun 30, 2022 $5.29B Aug 16, 2024
FY2023 Jun 30, 2021 $5.42B Aug 17, 2023
FY2022 Jun 30, 2020 $5.34B Aug 18, 2022
FY2021 Jun 30, 2019 $5.16B Aug 24, 2021
FY2020 Jun 30, 2018 $2.06B Aug 27, 2020
FY2019 Jun 30, 2017 $2.06B Sep 3, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $548.00M Aug 15, 2025
FY2025 Jun 30, 2024 $879.00M Aug 15, 2025
FY2024 Jun 30, 2023 $865.00M Aug 16, 2024
FY2023 Jun 30, 2022 $534.00M Aug 17, 2023
FY2022 Jun 30, 2021 $452.00M Aug 18, 2022
FY2021 Jul 1, 2020 $241.00M Aug 24, 2021
FY2021 Jun 30, 2020 $246.00M Aug 24, 2021
FY2020 Jul 1, 2019 $381.90M Aug 27, 2020
FY2020 Jun 30, 2019 $323.70M Aug 27, 2020
FY2019 Jun 30, 2018 $561.40M Sep 3, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $827.00M Aug 15, 2025
FY2025 Jun 30, 2024 $588.00M Aug 15, 2025
FY2024 Jun 30, 2023 $689.00M Aug 16, 2024
FY2023 Jun 30, 2022 $775.00M Aug 17, 2023
FY2022 Jun 30, 2021 $850.00M Aug 18, 2022
FY2021 Jun 30, 2020 $743.00M Aug 24, 2021
FY2020 Jun 30, 2019 $601.60M Aug 27, 2020
FY2019 Jun 30, 2018 $620.80M Sep 3, 2019
FY2019 Jun 30, 2017 $561.50M Sep 3, 2019
FY2019 Jun 30, 2016 $515.70M Sep 3, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2019 Jun 30, 2019 $5.31B Sep 3, 2019
FY2019 Jun 30, 2018 $3.67B Sep 3, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Aug 15, 2025
FY2025 Mar 31, 2025 0 Aug 15, 2025
FY2025 Dec 31, 2024 0 Aug 15, 2025
FY2025 Sep 30, 2024 0 Aug 15, 2025
FY2025 Jun 30, 2024 0 Aug 15, 2025
FY2025 Mar 31, 2024 0 Aug 15, 2025
FY2025 Dec 31, 2023 0 Aug 15, 2025
FY2025 Sep 30, 2023 0 Aug 15, 2025
FY2025 Jun 30, 2023 0 Aug 15, 2025
FY2024 Jun 30, 2022 0 Aug 16, 2024

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Aug 15, 2025
FY2025 Jun 30, 2024 0 Aug 15, 2025
FY2025 Jun 30, 2023 0 Aug 15, 2025
FY2024 Jun 30, 2022 0 Aug 16, 2024
FY2023 Jun 30, 2021 0 Aug 17, 2023
FY2020 Jun 30, 2020 0 Aug 27, 2020
FY2020 Mar 31, 2020 0 Aug 27, 2020
FY2020 Dec 31, 2019 0 Aug 27, 2020
FY2020 Sep 30, 2019 0 Aug 27, 2020
FY2020 Jun 30, 2019 0 Aug 27, 2020

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $845.00M Aug 15, 2025
FY2025 Jun 30, 2024 $722.00M Aug 15, 2025
FY2025 Jun 30, 2023 $723.00M Aug 15, 2025
FY2024 Jun 30, 2022 $732.00M Aug 16, 2024
FY2023 Jun 30, 2021 $742.00M Aug 17, 2023
FY2022 Jun 30, 2020 $761.00M Aug 18, 2022
FY2021 Jun 30, 2019 $680.00M Aug 24, 2021
FY2020 Jun 30, 2018 $526.80M Aug 27, 2020
FY2019 Jun 30, 2017 $489.10M Sep 3, 2019